The Kunitz Protease Inhibitor Domain of Protease Nexin-2 Inhibits Factor XIa and Murine Carotid Artery and Middle Cerebral Artery Thrombosis

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2012 Jun 8

PMID 22674803

Citations 20

Authors

Wenman Wu

Hongbo Li

Duraiswamy Navaneetham

Zachary W Reichenbach

Ronald F Tuma

Peter N Walsh

Affiliations

Soon will be listed here.

Abstract

Coagulation factor XI (FXI) plays an important part in both venous and arterial thrombosis, rendering FXIa a potential target for the development of antithrombotic therapy. The kunitz protease inhibitor (KPI) domain of protease nexin-2 (PN2) is a potent, highly specific inhibitor of FXIa, suggesting its possible role in the inhibition of FXI-dependent thrombosis in vivo. Therefore, we examined the effect of PN2KPI on thrombosis in the murine carotid artery and the middle cerebral artery. Intravenous administration of PN2KPI prolonged the clotting time of both human and murine plasma, and PN2KPI inhibited FXIa activity in both human and murine plasma in vitro. The intravenous administration of PN2KPI into WT mice dramatically decreased the progress of FeCl(3)-induced thrombus formation in the carotid artery. After a similar initial rate of thrombus formation with and without PN2KPI treatment, the propagation of thrombus formation after 10 minutes and the amount of thrombus formed were significantly decreased in mice treated with PN2KPI injection compared with untreated mice. In the middle cerebral artery occlusion model, the volume and fraction of ischemic brain tissue were significantly decreased in PN2KPI-treated compared with untreated mice. Thus, inhibition of FXIa by PN2KPI is a promising approach to antithrombotic therapy.

Citing Articles

Improvement in XIa Selectivity of Snake Venom Peptide Analogue BF9-N17K Using P2' Amino Acid Replacements.

Ding L, Zhai Z, Qin T, Lin Y, Shuang Z, Sun F Toxins (Basel). 2025; 17(1).

PMID: 39852976 PMC: 11769409. DOI: 10.3390/toxins17010023.

Characterization of Kunitz-Domain Anticoagulation Peptides Derived from Exotoxin Protein F6W77.

Sun F, Deng X, Gao H, Ding L, Zhu W, Luo H Toxins (Basel). 2024; 16(10).

PMID: 39453226 PMC: 11511053. DOI: 10.3390/toxins16100450.

SARS-CoV-2 infection results in upregulation of Plasminogen Activator Inhibitor-1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity.

Toomer K, Gerber G, Zhang Y, Daou L, Tushek M, Hooper J EJHaem. 2023; 4(2):324-338.

PMID: 37206290 PMC: 10188457. DOI: 10.1002/jha2.654.

A Factor XIa Inhibitor Engineered from Banded Krait Venom Toxin: Efficacy and Safety in Rodent Models of Arterial and Venous Thrombosis.

Chng W, Li A, Lim J, Leong E, Amran F, Kini R Biomedicines. 2022; 10(7).

PMID: 35884984 PMC: 9312835. DOI: 10.3390/biomedicines10071679.

WPK5, a Novel Kunitz-Type Peptide from the Leech Inhibiting Factor XIa, and Its Loop-Replaced Mutant to Improve Potency.

Zheng Y, Ji X, Liu Y, Jiang S, Yu X, Jia Z Biomedicines. 2021; 9(12).

PMID: 34944561 PMC: 8698482. DOI: 10.3390/biomedicines9121745.

References

Lin K, Liu R, Yeh T, Wang S, Liu H . Posterior ischemia during an attack of transient global amnesia. Stroke. 1993; 24(7):1093-5. DOI: 10.1161/01.str.24.7.1093. View

Minnema M, Friederich P, Levi M, von dem Borne P, Mosnier L, Meijers J . Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest. 1998; 101(1):10-4. PMC: 508534. DOI: 10.1172/JCI781. View

Swanson R, Morton M, Savalos R, Davidson C, Sharp F . A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990; 10(2):290-3. DOI: 10.1038/jcbfm.1990.47. View

Berliner J, Rybicki A, Kaplan R, Monrad E, Freeman R, Billett H . Elevated levels of Factor XI are associated with cardiovascular disease in women. Thromb Res. 2002; 107(1-2):55-60. DOI: 10.1016/s0049-3848(02)00190-1. View

Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M . Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. 2004; 103(10):3773-6. DOI: 10.1182/blood-2003-10-3422. View

Denis C, Methia N, Frenette P, Rayburn H, Hynes R, Wagner D . A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998; 95(16):9524-9. PMC: 21371. DOI: 10.1073/pnas.95.16.9524. View

Xu F, Davis J, Miao J, Previti M, Romanov G, Ziegler K . Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. Proc Natl Acad Sci U S A. 2005; 102(50):18135-40. PMC: 1312400. DOI: 10.1073/pnas.0507798102. View

Zhang Y, Scandura J, Van Nostrand W, Walsh P . The mechanism by which heparin promotes the inhibition of coagulation factor XIa by protease nexin-2. J Biol Chem. 1997; 272(42):26139-44. DOI: 10.1074/jbc.272.42.26139. View

Hanson W, Domek G, Horvath M, Goldenberg D . Rigidification of a flexible protease inhibitor variant upon binding to trypsin. J Mol Biol. 2006; 366(1):230-43. PMC: 1847787. DOI: 10.1016/j.jmb.2006.11.003. View

10.

Salomon O, Steinberg D, Koren-Morag N, Tanne D, Seligsohn U . Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008; 111(8):4113-7. DOI: 10.1182/blood-2007-10-120139. View

11.

Libourel E, Bank I, Meinardi J, Hamulyak K, Middeldorp S, Koopman M . Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica. 2002; 87(10):1068-73. View

12.

Stassen J, Lambeir A, Matthyssens G, Ripka W, Nystrom A, Sixma J . Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Thromb Haemost. 1995; 74(2):646-54. View

13.

Navaneetham D, Jin L, Pandey P, Strickler J, Babine R, Abdel-Meguid S . Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2. J Biol Chem. 2005; 280(43):36165-75. DOI: 10.1074/jbc.M504990200. View

14.

Ragni M, Sinha D, Seaman F, Lewis J, Spero J, Walsh P . Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood. 1985; 65(3):719-24. View

15.

Deng H, Bannister T, Jin L, Babine R, Quinn J, Nagafuji P . Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine. Bioorg Med Chem Lett. 2006; 16(11):3049-54. DOI: 10.1016/j.bmcl.2006.02.052. View

16.

Badellino K, Walsh P . Protease nexin II interactions with coagulation factor XIa are contained within the Kunitz protease inhibitor domain of protease nexin II and the factor XIa catalytic domain. Biochemistry. 2000; 39(16):4769-77. DOI: 10.1021/bi9925468. View

17.

Grzesiak A, Krokoszynska I, Krowarsch D, Buczek O, Dadlez M, Otlewski J . Inhibition of six serine proteinases of the human coagulation system by mutants of bovine pancreatic trypsin inhibitor. J Biol Chem. 2000; 275(43):33346-52. DOI: 10.1074/jbc.M006085200. View

18.

Bush A, Martins R, Rumble B, Moir R, Fuller S, Milward E . The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem. 1990; 265(26):15977-83. View

19.

Gruber A, Hanson S . Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood. 2003; 102(3):953-5. DOI: 10.1182/blood-2003-01-0324. View

20.

Broze Jr G, Warren L, Novotny W, Higuchi D, Girard J, Miletich J . The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988; 71(2):335-43. View